How to Sequence Therapies in Mycosis Fungoides

Caitlin M. Brumfiel, Meera H. Patel, Pranav Puri, Jake Besch-Stokes, Scott Lester, William G. Rule, Nandita Khera, Jason C. Sluzevich, David J. DiCaudo, Nneka Comfere, N. Nora Bennani, Allison C. Rosenthal, Mark R. Pittelkow, Aaron R. Mangold

Research output: Contribution to journalReview articlepeer-review


Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.

Original languageEnglish (US)
Article number101
JournalCurrent treatment options in oncology
Issue number11
StatePublished - Nov 2021


  • CTCL
  • Cutaneous T cell lymphoma
  • Cutaneous oncology
  • Lymphoma
  • Mycosis fungoides

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'How to Sequence Therapies in Mycosis Fungoides'. Together they form a unique fingerprint.

Cite this